NorthWest Biotherapeutics Inc (NWBO)

[TZOR]

From NW patient capital newsletter out today

The performance of the portfolio’s US biotech stocks was more mixed. Alkermes made a strong contribution, helped by a positive pipeline update that confirmed good progress in several of its treatments for diseases of the central nervous system. Northwest Biotherapeutics weakened, however, as the company came under increasing pressure to investigate recent allegations of financial improprieties and regulatory failure. We have engaged with the board on this matter and in a public filing to the U.S. Securities and Exchange Commission, we called for the appointment of an independent non-executive director and the convening of a special committee to investigate the allegations. According to the company, an investigation has commenced and we await its findings.